Curadh MTR Inc. is at the forefront of cancer treatment innovation, specifically focusing on molecularly targeted radiation (MTR) to combat solid tumors. The company is dedicated to developing second-generation radiopharmaceuticals that are designed to effectively eradicate these tumors. With a team of seasoned experts in oncology drug development, Curadh MTR is committed to advancing the science of MTR, which aims to enhance the precision and efficacy of cancer therapies. Their recent collaborations with industry leaders, such as NorthStar Medical Radioisotopes and SHINE Technologies, underscore their strategic approach to harnessing advanced radioisotopes for therapeutic applications.

The strategic partnerships formed by Curadh MTR are pivotal in the development of novel radiopharmaceuticals, particularly those utilizing Actinium-225, Terbium, and Lutetium. These collaborations aim to create targeted therapies that not only diagnose but also treat primary and metastatic solid tumors. By leveraging the unique properties of these radioisotopes, Curadh MTR is working to reshape cancer treatment paradigms, offering new hope to patients through innovative and precise therapeutic options. The company's focus on collaboration and cutting-edge research positions it as a leader in the evolving landscape of oncology.

United States

Curadh is pioneering the eradication of solid tumors through the new science of molecularly targeted radiation. With expertise in transitioning from Pre-Clinical to the Clinic, Curadh incorporates scientific excellence and product development strategy.

Curadh MTR Inc

Company Details